CD19 and neoplasm: Clinical experience with CD19 CAR T-cell therapies suggests two modes of tumor recurrence: antigen-positive and antigen-negative.43 One mechanism for acquired resistance in patients whose tumor cells retain membranous target expression is inadequate engraftment and persistence of CAR-modified T cells or impaired reactivity of adoptively transferred T cells potentially caused exhaustion.